W
hen pharmacologic agents are deemed necessary in the management of panic disorder (PD), current guidelines recommend treatment with a selective serotonin reuptake inhibitor (SSRI) 1Y3 with tricyclic antidepressants as alternative firstline agents. Benzodiazepines are either no longer recommended 3 or recommended only as a secondary treatment strategy. 1, 2 Alprazolam, a high-potency triazolobenzodiazepine, is supported in the treatment of PD by a number of short-term efficacy studies, 4Y10 and by 2 large, randomized, cross-national clinical trials demonstrating short-term efficacy and clinically acceptable tolerability against placebo 11, 12 and imipramine. 13 A few longerterm follow-up studies have demonstrated that alprazolam's treatment effect could be sustained for periods greater than 1 year. 14Y17 However, many studies have demonstrated alprazolam's propensity to produce clinically significant withdrawal symptoms and rebound anxiety. 18Y21 At a mechanistic level, these symptoms can be conceptualized as a long-term homeostatic adaptation to persistent F-aminobutyric acid (GABA) agonism, resulting in downregulation of the GABA-A system and consequent up-regulation of the GABA-mediated level of baseline anxiety. 22 Relative to other benzodiazepines, alprazolam has a short half-life, a high binding affinity to the GABA receptor, and a rapid onset and offset of action, pharmacokinetic properties that are associated with greater risk of dependency and withdrawal. 23 The intensity and prevalence of rebound anxiety with alprazolam accordingly seems greater than with other benzodiazepines. 24, 25 Alprazolam is increasingly being used as a drug of abuse 26 and is more toxic than other benzodiazepines in overdose. 27 Despite this, alprazolam prescribing remains common and continues to rise. 28Y30 Given its increasing use and potential to produce adverse outcomes, the role of alprazolam in PD deserves critical reevaluation. We performed a meta-analysis to determine whether the weight of clinical evidence suggests that alprazolam is superior to other benzodiazepines in the management of PD.
METHODS
For a full description of methods please refer to the Supplemental Material (Supplemental Digital Content 1, http://links.lww.com/JCP/A76). A systematic search on major electronic databases (Cochrane Controlled Trials Register, PubMed, Embase, and PsycINFO) using a Boolean Search Strategy with key words ''panic disorder'' AND (''alprazolam'' OR ''Xanax'') was conducted on April 13, 2010. Inclusion criteria required studies to be single-or double-blind, randomized controlled trials comparing 2 or more doses of alprazolam with any alternative benzodiazepine for the treatment of patients 18 years or older with a diagnosis of PD (or agoraphobia with panic attacks) according to Diagnostic and Statistical Manual of Mental Disorders, Third Edition or Fourth Edition, Text Revision, criteria. One or more of the following outcomes also had to be reported: change in panic attack frequency (PAF; primary meta-analysis outcome), change in Hamilton Anxiety Scale (HAM-A) score, proportion of patients free of panic attacks at study conclusion, self-or clinician-rated global improvement measures, or a measure of anxiety or depressive symptoms at study conclusion. Two authors independently reviewed the titles and abstracts of 548 articles initially identified by our search strategy and retrieved 30 articles for further evaluation. Sixteen of these articles had potentially relevant data and were reviewed by all authors. Each author independently concluded that only 8 of these studies met inclusion criteria. Using a standardized data extraction work sheet, 2 authors independently extracted study design, patient population, number of patients enrolled and randomized, comparator benzodiazepine, the prespecified meta-analysis outcomes, and data on adverse effects from each of the 8 studies. Disagreements were resolved by discussion after rereview of the articles. Quality assessment was undertaken in accordance with the Cochrane Handbook for Systematic Reviews of Interventions. 33 Metaanalysis for each outcome was conducted using a random effects model by the method of DerSimonian and Liard. 34 Sensitivity analyses were performed as described in the supplementary material (Supplemental Digital Content 1). Data synthesis and all statistical analyses were completed using STATA version 11, 35 using 2-sided tests at a significance level of 0.05.
RESULTS

Search Results and Description of Studies
Eight studies met inclusion criteria, 6 ,36Y42 and basic descriptors of each study are summarized in Table 1 . Summing across all studies, at least 631 patients were randomized to either alprazolam or comparator benzodiazepine arms. This underestimates the true number of enrolled subjects because 1 article reported the number of patients completing the trial but not the number of patients initially randomized. 37 
Quality Assessment
None of the included studies specified their method of randomization. Five studies 36, 38, 39, 41, 42 clearly described an adequate blinding process, and in 3 studies, 6 ,37,40 the blinding process was unclear. Three studies 38, 41, 42 performed intentionto-treat (ITT) analyses for all outcomes, 3 studies 36,39,40 reported ITT analyses for some outcomes, and 2 studies 6,37 reported results only on those patients completing the trial.
Outcomes
Panic Attack Frequency
Five studies reported the mean (SD) for PAF in each arm at both baseline and final assessment and could be used in the pooled analysis of this outcome. 6,38,40Y42 The change in mean PAF from baseline to final evaluation ($PAF) was summarized for alprazolam and comparator arms in each trial. A trial-level summary measure was obtained by subtracting the alprazolam arm $PAF from the comparator arm $PAF to obtain a ''difference in $PAF.'' In the pooled analysis, there was no significant difference in mean PAF improvement between the alprazolam and comparator arms (weighted mean difference in $PAF of 0.6 panic attacks per week, 95% confidence interval [CI], j0.3 to 1.6; Fig. 1 : PAF Forest Plot). Significant between-study heterogeneity prompted post hoc removal of a study with a particularly low mean weighted baseline PAF, but reanalysis of the remaining studies neither changed the conclusion of the original analysis nor improved the between-study heterogeneity (see Supplemental Material, Supplemental Digital Content 1).
Hamilton Anxiety Scale
Six studies reported mean HAM-A scores with SDs at both baseline and final evaluation. 6 ,36Y38,40,42 A trial-level summary measure, the ''difference in $HAM-A,'' was obtained by a method analogous to that described for the ''difference in $PAF.'' The pooled analysis demonstrated no difference in mean HAM-A improvement between alprazolam and comparator benzodiazepine 
Proportion of Panic AttackYFree Patients
Six trials reported data on the proportion of subjects in each arm who were ''panic attackYfree'' at trial conclusion, defined as either no reported panic attacks for 1 week 38Y40,42 or 2 weeks 36, 41 before the final assessment. Only 3 studies clearly describe performing an ITT analysis 38, 41, 42 and the remainder report outcome data only for subjects that completed the trial. The main analysis for this end point was therefore performed using data from all trials for ''completers'' only. The pooled results for this analysis demonstrated no significant difference between alprazolam and comparator benzodiazepines (pooled relative risk, 1.1; 95% CI, 0.9Y1.4; Supplementary Figure S4 [Supplemental Digital Content 3]: Forest Plot for PA-Free, http://links.lww.com/JCP/A81), with no significant between-study heterogeneity (I 2 = 0.36, heterogeneity W 2 P = 0.17). As described further in the supplementary methods and results, ''conservative ITT'' and ''pharmaceutical optimists' ITT'' sensitivity analyses were then performed to explore the robustness of this result, and the conclusions of these sensitivity analyses did not differ from those of the main analysis.
One additional sensitivity analysis was performed after removing the only study with a crossover design. 39 This had no substantial effect on the point estimate, CI, or conclusion of the analysis among completers (pooled relative risk, 1.1; 95% CI, 0.9Y1.4) or of the accompanying sensitivity analyses.
Other Prespecified Outcome Measures
For self-and clinician-rated global improvement measures and measures of anxiety or depressive symptoms at study conclusion, 2 or fewer studies reported results on common outcome measurement scales. Because this would impair both the validity and interpretability of quantitative data synthesis, a metaanalysis on these outcomes was not performed.
Adverse Effects
Definitions of adverse effects were inconsistent across the 8 studies. Moreover, all authors felt that the adverse effect surveillance and reporting in all studies were of poor quality. As such, the authors agreed a quantitative synthesis of adverse effect data was not appropriate. The most commonly reported adverse effect was sedation, reported in 6 studies.
37Y42 Participant dropout rates due to adverse effects were reported in 6 studies, 36 ,38Y42 and this did not differ between the alprazolam and comparator arms. No study reported a clinically significant difference in tolerability between alprazolam and comparative benzodiazepine. No study reported data on tolerance or dependence to administered agents.
Examining for Small Study Effects and Potential Publication Bias
We examined for small study effects (for which publication bias is 1 explanation) using the ''difference in $PAF'' outcome. The Egger test for small study effects suggested no such effects were present (P = 0.12; see Supplementary Figure S7 tend to favor alprazolam (see Supplemental Figure S8 [Supplemental Digital Content 5]: Begg Funnel Plot for Small Study Effects, http://links.lww.com/JCP/A83). Because the appearance and validity of these statistical tests can be affected by the choice of outcome measure, by the choice of study weight on the y axis, and particularly by the small number of studies and significant between-study heterogeneity in this meta-analysis, interpretation of these results is difficult.
DISCUSSION
This quantitative meta-analysis of all relevant single-or double-blind, randomized controlled trials did not demonstrate an advantage of alprazolam over other benzodiazepines in the management of adult patients with PD or agoraphobia with panic attacks.
Our meta-analysis has several features that may introduce bias and limit the strength of its conclusions. There were only a small number of relevant studies. There was significant betweenstudy heterogeneity in study design, comparator benzodiazepine choice, and in outcome measures reported. None of the studies specified their method of randomization. Three studies 6, 37, 40 did not clearly describe their blinding processes. Only 4 studies clearly described performing an ITT analysis for all outcomes. 36, 38, 40, 42 Begg test suggested that small study effects were present, raising the possibility of publication bias. The use of broad measures of PD severity (eg, HAM-A, counts of PAF) in included studies is a further limitation. Such measures lack the advantages of specific ratings scales for PD (eg, Panic and Agoraphobia Scale 43 and PD Severity Scale 44 ) that measure across multiple domains of PD symptoms and have greater sensitivity in detecting placebo-drug differences in PD. The use of broad measures may not provide reliable evidence of an overall treatment effect, specifically in domains not associated with panic attacks (eg, quality of life). 45 A further limitation of this data set is the absence of systematic measures of the known adverse event profile of these agents, restricting risk-benefit assessment.
Despite these limitations, this meta-analysis suggests that alprazolam is no more effective than other benzodiazepines in the treatment of PD. This needs to be considered along with alprazolam's propensity for tolerance, dependence, and toxicity. It is unlikely that its use is restricted to PD and is likely to extend into other mood and anxiety disorders where evidence of preferential efficacy and safety in contrast to other therapies is also absent. Current practice guidelines for PD recommend the use of evidence-based psychological therapies 46 (eg, cognitive behavioral therapy) or SSRIs as first-line monotherapy 1Y3 for PD. The advantage of combining therapies remains unclear. 47, 48 A few studies have compared the utility of high-potency benzodiazepines, primarily clonazepam, as adjunctive therapy to SSRIs. 49, 50 These studies suggest possible short-term advantages to coadministration, but this effect is not sustained beyond a few weeks of treatment. No study has used alprazolam as an adjunct treatment to date.
When 54, 55 in the treatment of PD. In the short term, alprazolam has not shown clinically different tolerability as compared with other agents; however, studies were not powered for noninferiority or for adverse events.
For the longer term, however, alprazolam has consistently demonstrated significant rebound anxiety, withdrawal symptoms, 23Y27 and a propensity for abuse. 32 Alprazolam is also a commonly used drug in overdose situations, 56, 57 where it exhibits greater toxicity than other benzodiazepines. 33 It is likely that these effects relate to alprazolam's short half-life, high potency, and multiple daily dosing requirements. 30, 31 For these reasons, clonazepam, a high-potency benzodiazepine with longer halflife, 58 has received attention as an alternative to alprazolam, particularly in patients experiencing interdose anxiety. 59 A few studies have demonstrated successful discontinuation of clonazepam, 54, 60 with decreased withdrawal symptoms attributed to its prolonged elimination half-life. 58 As previously mentioned, alprazolam prescription rates are increasing 28Y30 despite no longer being a recommended firstline treatment strategy for PD. 1Y3 Alprazolam remains the most prescribed psychotropic drug in the United States. 61 This increase in prescription volume, even if a proportion is attributable to use in other disorders (eg, generalized anxiety disorder), is not supported by clinical guidelines or new clinical trial data. In a qualitative study of youths 62 attending drug treatment, addiction to alprazolam was perceived to occur very early in treatment, and medical professionals were identified as the drug's greatest facilitators. Inappropriate prescription and management of a medication is more likely to occur when the prescriber is less familiar or has less experience with the appropriate use of the medication. Education campaigns 63 and medication restrictions 63 have been partially effective in reducing inappropriate alprazolam prescribing. However, given the risk versus benefit equation for alprazolam use and the wider availability of more commonly used alternatives, a critical reevaluation of its place in the future treatment of PD is warranted.
